CTXRHIGH SIGNALRISK10-K

CTXR has elevated going concern warnings to the top of their risk factors while significantly increasing inventory (+169.5%) amid persistent funding challenges and strategic uncertainty.

The company has restructured their risk disclosures to emphasize going concern doubts and immediate funding needs, suggesting heightened financial distress despite having launched a product. The mention of "alternative strategic paths" exploration indicates potential sale, merger, or other major strategic pivot under consideration due to operational pressures.

Comparing 2025-12-23 vs 2024-12-27View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company attempting to scale commercial operations with inventory surging 169.5% to $22.3M and current assets nearly doubling, but this growth is funded by increased liabilities (+25.5%) rather than strong cash generation. While R&D expenses declined 23.1% to $9.2M, the modest cash increase to just $4.3M against $44.9M in current liabilities creates a precarious liquidity position. The inventory buildup suggests commercial preparation, but the liability growth and minimal cash cushion reflect the funding challenges prominently featured in their updated risk disclosures.

FINANCIAL STATEMENT CHANGES
Capital Expenditure
Cash Flow
+278.9%
$2K→$7K

Capital expenditure jumped 278.9% — major investment cycle underway; assess returns on deployment.

Inventory
Balance Sheet
+169.5%
$8.3M→$22.3M

Inventory surged 169.5% — growing significantly faster than typical sales pace; potential demand softening or supply chain overcorrection.

Current Assets
Balance Sheet
+96.4%
$14.2M→$27.9M

Current assets grew 96.4% — improving short-term liquidity or inventory/receivables build.

Interest Expense
P&L
-30.8%
$16K→$11K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Cash & Equivalents
Balance Sheet
+30.8%
$3.3M→$4.3M

Cash position surged 30.8% — strong cash generation or capital raise providing significant financial cushion.

Total Liabilities
Balance Sheet
+25.5%
$42.5M→$53.4M

Liabilities increased 25.5% — monitor debt-to-equity ratio and interest coverage.

Current Liabilities
Balance Sheet
+25.4%
$35.8M→$44.9M

Current liabilities rose 25.4% — increased short-term obligations, watch current ratio.

R&D Expense
P&L
-23.1%
$11.9M→$9.2M

R&D spending cut 23.1% — could signal cost discipline or concerning reduction in innovation investment.

Total Assets
Balance Sheet
+12.2%
$116.7M→$130.9M

Asset base grew 12.2% — expansion through organic growth, acquisitions, or capital deployment.

LANGUAGE CHANGES
NEW — 2025-12-23
PRIOR — 2024-12-27
ADDED
Form 10-K Summary 82 Signatures 83 NOTES In this annual report on Form 10-K, and unless the context otherwise requires, the Company, we, us and our refer to Citius Pharmaceuticals, Inc.
These risks include, but are not limited to, the following: Our independent registered public accounting firm s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern.
We require substantial additional funding, which may not be available on acceptable terms, or at all.
Failure to obtain this necessary capital when needed on acceptable terms, or at all, or execute on alternative strategic paths, could force us to delay, limit, reduce or terminate our commercialization efforts and business operations.
We have a history of net losses and expect to incur losses for the foreseeable future.
+7 more — sign up free →
REMOVED
Form 10-K Summary 65 Signatures 66 i NOTES In this annual report on Form 10-K, and unless the context otherwise requires, the Company, we, us and our refer to Citius Pharmaceuticals, Inc.
These risks include, but are not limited to, the following: We have a history of net losses and expect to incur losses for the foreseeable future.
Our independent registered public accounting firm s report includes an explanatory paragraph stating that there is substantial doubt about our ability to continue as a going concern.
We need to secure additional financing in the near future to complete the development of our other current product candidates and support our operations.
We are primarily a late-stage development company with an unproven business strategy and may never achieve commercialization of our therapeutic product candidates or profitability.
+7 more — sign up free →
MORE RISK SIGNALS
CAPSHIGHCAPS underwent a major business expansion through acquisitions while experiencin...
2026-04-16
KALAHIGHKALA has undergone a dramatic business transformation with massive share dilutio...
2026-04-15
RAINHIGHRain Enhancement Technologies underwent a financial restatement revealing signif...
2026-04-15
POLAHIGHPOLA experienced severe financial deterioration with gross profit turning negati...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →